Latest Genzyme Stories
New board appointments extend CHI’s network and bring new industry expertise in medical devices and rare diseases. La Jolla, CA (PRWEB) January 23, 2015
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan.
Former head of rare diseases at Genzyme brings a 20-year track record of delivering successful, innovative products to patients throughout the world PHILADELPHIA, Dec.
CAMBRIDGE, Mass., Nov.
INCLINE VILLAGE, Nev., Nov.
PARIS, October 27, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014.
DALLAS, October 17, 2014 /PRNewswire/ -- The Middle East and Africa Solid Organ Transplant Immunosuppressant Industry 2014 Deep Research Report is of 120 pages and published
- Stowe to be Joined by Leading Neurologists and People Living with the Disease for Live Events Nationwide - CAMBRIDGE, Mass., Oct.
CARLSBAD, Calif., Sept. 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc.
- The word or words serving to define another word or expression, as in a dictionary entry.